A型肾被成功地转化成O型,使用酶疗法,并移植到一个脑死病人,避免被拒绝。 A type A kidney was successfully converted to type O using enzyme therapy and transplanted into a brain-dead patient, avoiding rejection.

用不列颠哥伦比亚大学开发的酶技术成功地将A型捐血者的肾移植为O型,并移植为脑死接受者,这是人类首次进行此类试验。 A kidney from a blood type A donor was successfully converted to type O using enzyme technology developed at the University of British Columbia and transplanted into a brain-dead recipient, marking the first human trial of its kind. 肾脏转换后正常运转两天,没有高急性反应,到第三天只有轻微的免疫反应。 The converted kidney functioned normally for two days without hyperacute rejection, with only mild immune response observed by day three. 酶治疗除去A型抗原,引发排斥,有可能使器官在血型间使用。 The enzyme treatment removed type-A antigens that trigger rejection, potentially enabling organs to be used across blood types. 这一程序已经发展了十多年,可以扩大捐助者库,减少移植等待时间。 The procedure, over a decade in development, could expand the donor pool and reduce transplant wait times. 下一步是对临床试验进行监管批准,由UBC附带药草生物医学牵头进行这项工作。 Regulatory approval for clinical trials is next, with UBC spin-off Avivo Biomedical leading the effort.